Laura Asnaghi1, Hind Alkatan2, Alka Mahale2, Maha Othman2, Saeed Alwadani3, Hailah Al-Hussain2, Sabah Jastaneiah2, Wayne Yu4, Azza Maktabi2, Deepak P Edward5, Charles G Eberhart6. 1. Department of Pathology, Johns Hopkins University, School of Medicine, Baltimore, Maryland, United States. 2. King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia. 3. Department of Pathology, Johns Hopkins University, School of Medicine, Baltimore, Maryland, United States Department of Ophthalmology, Johns Hopkins University, School of Medicine, Baltimore, Maryland, United States Department of Ophthalmology, King Saud University, Riyadh, Saudi Arabia. 4. Microarray Core Facility, Sidney Kimmel Cancer Center, Johns Hopkins University, School of Medicine, Baltimore, Maryland, United States. 5. King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia Department of Ophthalmology, Johns Hopkins University, School of Medicine, Baltimore, Maryland, United States. 6. Department of Pathology, Johns Hopkins University, School of Medicine, Baltimore, Maryland, United States Department of Ophthalmology, Johns Hopkins University, School of Medicine, Baltimore, Maryland, United States Department of Oncology, Johns Hopkins University, School of Medicine, Baltimore, Maryland, United States.
Abstract
PURPOSE: Little is known about the molecular alterations that drive formation and growth of conjunctival squamous cell carcinoma (cSCC). We therefore sought to identify genetic changes that could be used as diagnostic markers or therapeutic targets. METHODS: The DNA extracted from 10 snap-frozen cSCC tumor specimens and 2 in situ carcinomas was analyzed using array-based comparative genomic hybridization (aCGH), and further examined with NanoString and quantitative PCR. RESULTS: The number of regions of DNA loss ranged from 1 to 23 per tumor, whereas gains and amplifications ranged from 1 to 15 per tumor. Most large regions of chromosomal gain and loss were confirmed by NanoString karyotype analysis. The commonest alteration was amplification of 8p11.22 in 9 tumors (75%), and quantitative PCR analysis revealed 100-fold or greater overexpression of ADAM3A mRNA from 8p11.22 locus. In addition, recurring losses were observed at 14q13.2 and 22q11.23, both lost in 5 (42%) of the 12 tumors, and at 12p13.31, lost in 4 (33%) of the 12 samples. Of the eight loci associated with the DNA damage repair syndrome xeroderma pigmentosum, three showed loss of at least one allele in our aCGH analysis, including XPA (9q22.33, one tumor), XPE/DDB2 (11p11.2, one tumor) and XPG/ERCC5 (13q33.1, three tumors). CONCLUSIONS: Conjunctival SCC contains a range of chromosomal alterations potentially important in tumor formation and growth. Amplification of 8p11.22 and overexpression of ADAM3A suggests a potential role for this protease. Our findings also suggest that defects in DNA repair loci are important in sporadic cSCC. Copyright 2014 The Association for Research in Vision and Ophthalmology, Inc.
PURPOSE: Little is known about the molecular alterations that drive formation and growth of conjunctival squamous cell carcinoma (cSCC). We therefore sought to identify genetic changes that could be used as diagnostic markers or therapeutic targets. METHODS: The DNA extracted from 10 snap-frozen cSCC tumor specimens and 2 in situ carcinomas was analyzed using array-based comparative genomic hybridization (aCGH), and further examined with NanoString and quantitative PCR. RESULTS: The number of regions of DNA loss ranged from 1 to 23 per tumor, whereas gains and amplifications ranged from 1 to 15 per tumor. Most large regions of chromosomal gain and loss were confirmed by NanoString karyotype analysis. The commonest alteration was amplification of 8p11.22 in 9 tumors (75%), and quantitative PCR analysis revealed 100-fold or greater overexpression of ADAM3A mRNA from 8p11.22 locus. In addition, recurring losses were observed at 14q13.2 and 22q11.23, both lost in 5 (42%) of the 12 tumors, and at 12p13.31, lost in 4 (33%) of the 12 samples. Of the eight loci associated with the DNA damage repair syndrome xeroderma pigmentosum, three showed loss of at least one allele in our aCGH analysis, including XPA (9q22.33, one tumor), XPE/DDB2 (11p11.2, one tumor) and XPG/ERCC5 (13q33.1, three tumors). CONCLUSIONS: Conjunctival SCC contains a range of chromosomal alterations potentially important in tumor formation and growth. Amplification of 8p11.22 and overexpression of ADAM3A suggests a potential role for this protease. Our findings also suggest that defects in DNA repair loci are important in sporadic cSCC. Copyright 2014 The Association for Research in Vision and Ophthalmology, Inc.
Authors: Gary K Geiss; Roger E Bumgarner; Brian Birditt; Timothy Dahl; Naeem Dowidar; Dwayne L Dunaway; H Perry Fell; Sean Ferree; Renee D George; Tammy Grogan; Jeffrey J James; Malini Maysuria; Jeffrey D Mitton; Paola Oliveri; Jennifer L Osborn; Tao Peng; Amber L Ratcliffe; Philippa J Webster; Eric H Davidson; Leroy Hood; Krassen Dimitrov Journal: Nat Biotechnol Date: 2008-02-17 Impact factor: 54.908
Authors: Sai Wah Tsao; Yim Ling Yip; Chi Man Tsang; Pei Shin Pang; Victoria Ming Yi Lau; Guitao Zhang; Kwok Wai Lo Journal: Oral Oncol Date: 2014-03-12 Impact factor: 5.337
Authors: Jennifer Barrow; Martyna Adamowicz-Brice; Maria Cartmill; Donald MacArthur; James Lowe; Keith Robson; Marie-Anne Brundler; David A Walker; Beth Coyle; Richard Grundy Journal: Neuro Oncol Date: 2010-12-07 Impact factor: 12.300
Authors: Alka Mahale; Hind Alkatan; Saeed Alwadani; Maha Othman; Maria J Suarez; Antoinette Price; Hailah Al-Hussain; Sabah Jastaneiah; Wayne Yu; Azza Maktabi; Edward P Deepak; Charles G Eberhart; Laura Asnaghi Journal: Mod Pathol Date: 2016-02-26 Impact factor: 7.842
Authors: M Adelita Vizcaino; Abeer Z Tabbarah; Laura Asnaghi; Azza Maktabi; Allen O Eghrari; Divya Srikumaran; Charles G Eberhart; Fausto J Rodriguez Journal: Hum Pathol Date: 2019-09-05 Impact factor: 3.466
Authors: Priyadharsini Nagarajan; Christian El-Hadad; Stephen K Gruschkus; Jing Ning; Courtney W Hudgens; Oded Sagiv; Neil Gross; Michael T Tetzlaff; Bita Esmaeli Journal: Invest Ophthalmol Vis Sci Date: 2019-05-01 Impact factor: 4.799